Sunday 25 June
12.00-14.00
Registration
14.00-16.00
New regimens for TB and TPP to shape the future of TB treatment
​
Chair: Daniela Maria Cirillo, Philip Supply
GL01 Samuel Schumacher, WHO, Geneva
Target Regimen Profiles (TRPs) for TB treatment - VIRTUAL
​
GL02 Francesca Conradie, WITS HEALTH, University of the Witwatersrand, South Africa
TB universal regimens; pros and cons for adults and pediatric population
​
GL03 Christian Lienhardt, French Institute for. Research on Sustainable Development (IRD), Montpellier
New regimens, new TBdrugs: what to expect? - VIRTUAL
GL04 Saskia Den Boon, WHO
Target Product Profiles for Tests for TB Treatment Monitoring and Optimization
​
​
16.00-16.30
Coffee Break
16.30-17.00
Student mini-symposium on new drugs and DR TB (5 min flash talks)
Chair: Stefan Niemann, Silva Tafaj
P38 Marco Schiuma , Department of Biomedical & Clinical Sciences "Luigi Sacco", Università degli Studi di Milano, Italy.
Rifampicin and isoniazid dosage adjustment according to TDM and acetylator status: a single centre prospective observational study
​
P63 Jihad Snobre, Mycobacteriology Unit, Biomedical Sciences, Institute of Tropical Medicine (ITM), Antwerp
Exploring the impact of mutations in Rv0678 gene on bedaquiline resistance in Mycobacterium tuberculosis: insights from computational biostructural proteomics
P61 Ilariaa Iannucci, Universita Vita-Salute San Raffaele, Milan
In vitro susceptibility testing of GSK656 against Mycobacterium tuberculosis complex isolates to establish the epidemiological cut-off values and MIC distribution
​
P08 Emilie Rousseau, Molecular and Experimental Mycobacteriology, Research Center Borstel,
Mutation rates in strains of different Mycobacterium tuberculosis lineages associated with emergence of multi-drug resistant tuberculosis
​
P30 Darshaalini Nadarajan, National and Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
Prospective evaluation of targeted next-generation sequencing of Mycobacterium tuberculosis complex strains in routine diagnostics in Germany.
​
P35 Virginia Batignani, San Raffaele Scientific Institute
Xpert MTB/XDR assay for the rapid diagnosis of TB resistance. A country wide cross sectional observational prospective study from Pakistan
​
17:00-18.45
Opening session
​
Chair: Daniela Maria Cirillo, Silva Tafaj
GL05 Opening Keynote Silvia Bino, Head of Infectious Diseases, Institute of Public Health
High priority and emerging pathogens in Albania
​
GL06 Gertrud Meissner Award presented by S. Niemann
GL07 Gardner Middlebrook Award presented by BD
Monday 26 June
08:00-09:00
Registration
09:00-10:30
Host pathogens interaction in M tuberculosis
Chair: Leen Rigouts, Matthias Merker
GL08 Margarida Saraiva, Department of Microbiology and Immunology, McGill University
Study of host pathogen interactions in TB by using an in clinico to in vitro to in vivo approach
​
GL09 Stephanie Boisson-Dupuis, Rockefeller University, NYC
Novel genetic etiologies in susceptibility to tuberculosis
​
OR01 Sarah Danchuk, McGill University, Montreal,
Understudied and overlooked: Characterizing Mycobacterium orygis
​
OR02 Paolo Miotto, San Raffael Scientific Institute
Mycobacterial extracellular vesicles (MEVs) as a novel option in bladder cancer therapy
​
OR03 Issy Schiavi, St. George's University of London
Mycobacterial interactions promote Vγ9Vδ2 T cells to target and kill cancer cells
​
OR04 Jana Schoenfeld, Research Center Borstel, Germany
Uncovering epigenetic changes in early-stage MTBC-infected macrophages
​
​
10:30-11:00
Coffee Break
11:00-12:45
Resistance to new antitubercular drugs and clinical implications
​
Chair: Francesca Conradie, Philip Supply
GL10 Claudio Köser, Cambridge University
The X(DR)-Files – I want to believe
​
OR05 Kurt Wollenberg, National Institute of Allergy and Infectious Diseases
Molecular evolutionary analysis of a clade of closely-related Delamanid-resistant Mycobacterium tuberculosis (M.tb) strains from Eastern Europe and Central Asia.
​
OR06 Annelies Van Rie, University of Antwerp
Bayesian probability of bedaquiline resistance to guide rifampicin-resistant tuberculosis treatment
​
OR07 Valeriu Crudu, State University of Medicine and Pharmacy, Chisinau, Moldova
Evolution of resistance to new drugs in high tuberculosis burden country.
​
OR08 Sonia Borrell, Swiss Tropical and Public Health Institute-University of Basel
Drug-specific differential culturability in diverse strains of Mycobacterium tuberculosis
​
OR09 Siavash Valafar, Chicago Medical School
Prognosis and Prevention of Antibiotic Resistance in Mycobacterium tuberculosis: the Isoniazid (INH) Case Study
12:45-13:30
Lunch
13:30-14:30
Poster Session 1
14:30-15:45
Future of next generation sequencing
​
Chair: Kristin Kremer, Andrea Cabibbe
GL11 Philip Fowler, University of Oxford
Whole genome sequencing for tuberculosis: it works, how do we get it used more widely?
​
OR10 Vincent Rennie, Family Medicine and Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp
The MAGMA platform for global and equitable WGS-guided management of drug resistant TB and TB control
​
OR11 Maximilian Marin Department of Biomedical Informatics, Harvard Medical School
Analysis of the limited Mtb pan-genome reveals potential pitfalls of pan-genome analysis approaches
​
OR12 Christophe Sola, INSERM UMR1137
TB-ANNOTATOR: A scalable web application that allows in-depth analysis of very large sets of publicly available Mycobacterium tuberculosis complex genomes.
​
15:45-16:15
Coffee Break
16:15-17:30
Animal models to study mycobacterial infections
​
Chair: Margarida Saraiva, Leen Rigouts
GL12 Pere-Joan Cardona Iglesias, Hospital Universitari Germans Trias i Pujol, Badalona
Mouse models to study TB pathogenesis
​
GL13 Nicola Lore, IRCCS San Raffaele Scientific Institute
Mouse models to study host-pathogens interaction in M.abscessuss lung infections
​
OR13 Maria Vidal Ramos, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona
Mycobacterium tuberculosis infecting Drosophila melanogaster: first insights of the new latent tuberculosis infection model.
17:30-19:00
Round Table: Bordering EU countries: Situation, challenges and way out (Availability and affordability of NGS technologies to control DR TB, Viral Diseases and AMR)
​
Chair: Silvia Bino, Hasan Hafizi, University Hospital for Lung diseases, Tirana
Round table discussion
Tuesday 27 June
08:30-09:00
Registration
09:00-10:45
Host pathogens interaction in NTMs
​
Chair: Troels Lillebaek, Eva Sodja
GL14 Lucas Boeck, University Hospital Basel
Phenogenomic analyses: linking mycobacterial behaviours to molecular mechanisms
​
GL15 Stephen Leon Icaza, IPBS-Toulouse
The organoid revolution to assess mycobacterial pulmonary infections
​
OR14 Federico Di Marco, San Raffaele Scientific Institute, Emerging Bacterial Pathogens Unit
Single cells RNA sequencing of peripheral blood mononuclear cells reveals hyperinflammatory monocytes in patients with Mycobaterium abscessus pulmonary disease
​
OR15 Ivana Palucci, Catholic University of Sacred heart, Rome
Cysteamine/Cystamine exert anti-Mycobacterium abscessus activity alone or in combination with amikacin.
​
OR16 Francesca Nicola, San Raffaele Scientific Institute
The spatial distribution of type 1 and type 17 immune transcriptomics profiles in murine models of chronic lung infection by opportunistic pathogens
10:45-11:15
Coffee Break
11:15-13:00
Innovation in diagnostics
​
Chair: Christophe Sola, Paolo Miotto
GL16 Morten Ruhwald, FIND, Geneva
Future trends and innovation in diagnostics for TB - VIRTUAL
​
OR17 Onya Opota, Institute of Microbiology, Lausanne University Hospital and University of Lausanne
Nanomotion technology in combination with machine learning: a new approach for rapid antibiotic susceptibility test for Mycobacterium tuberculosis
​
OR18 Leen Rigouts, Institute of Tropical Medicine, Antwerp, Belgium
Successful Myocbacterium tuberculosis culture isolation from spiked tongue swabs processed by the Kudoh-Ogawa or cetylpyridinium chloride methods.
OR19 Faridath Massou, Laboratoire de Reference des Mycobacteries
Deeplex Myc/TB directly on sputum detects more mixed infections and heteroresistance compared to culture-based whole genome sequencing.
​
OR20 Margaretha de Vos, FIND, Geneva
Diagnostic accuracy of upper airway swabs and saliva with Xpert MTB/RIF Ultra for the detection of tuberculosis in adults
​
OR21 Kristin Kremer, KNCV Tuberculosis Foundation
The simple one-step stool processing method to diagnose tuberculosis is robust enough for global scale up
13:00-14:00
Lunch
14:00-15:00
Poster Session 2
15:00-16:15
Innovation in diagnostics (cont.)
​
Chair: Leen Rigouts, Richard Anthony
OR22 Emilyn Costa, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Tow
Evaluating DNA extraction commercial kits from Mycobacterium tuberculosis clinical primary liquid (MGIT) culture for downstream sequencing applications
OR23 Miguel Moreno, Biomedicine Institute of Valencia IBV-CSIC
The role of MIC shifts as early markers of treatment failure in tuberculosis
​
OR24 Tim Bull, St. George's University of London
Ph neutral anti-microbial peptide-based decontamination of samples enhances recovery in culture of low load Mycobacterium tuberculosis
​
OR25 Erik Svensson, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen
Detection of Mycobacterium tuberculosis and resistance mutations in different sample types using FluoroType MTBDR v2. A study from Germany and Denmark.
​
OR26 Dmytro Butov, Kharkiv National Medical University
Consideration of the results of the Xpert MTB/RIF method on the treatment outcome of patients with M\XDR pulmonary tuberculosis during the COVID-19 epidemic in Kharkiv region, Ukraine
16:15-16:45
Coffee Break
16:45-17:30
General Assembly
Wednesday 28 June
08.30-10.00
Session Non tuberculous mycobacteria, epidemiology and more
​
Chair: Troels Lillabaek, Dorte Bek Folkvardsen
GL17 Victor Næstholt Dahl, Aarhus University Hospital
Global trends of pulmonary infections with nontuberculous mycobacteria
​
OR27 Margo Diricks, Research center Borstel
Exploring the plasmidome of non-tuberculous mycobacteria
​
OR28 Nils Wetzstein, Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main
Genomic landscape of M. avium complex in Central Germany
​
OR29 Xenia Iversen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark
Frozen in Time: Unlocking the History of Nontuberculous Mycobacteria
​
OR30 Sandra Salillas-Berges, Radboud University Medical Center
Rifampicin substituted by clofazimine in the recommended therapy of Mycobacterium avium pulmonary disease: a hollow-fibre model study
10.00-10:30
Coffee Break
10:30-11.30
Session Biology of Pathogen
Chair: Erik Svenson, Mireia Coscolla
​
OR36 Rina De Zwaan, National Institute for Public Health and the Environment
Next-generation sequencing cluster typing; All single nucleotide polymorphisms are equal but some are more equal than others
​
OR31 Kerri Malone EMBL-EBI
Fine-scale evolution of Mycobacterium tuberculosis growth rate
​
OR32 Philip Supply, Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille
CRISPR-Cas molecular memory in Mycobacterium canettii reveals the putative ancestral environmental origin of M. tuberculosis
​
OR34 Sladjana Prisic, University of Hawaii at Manoa
From bad to worse: Does zinc limitation make M. tuberculosis more virulent?
11:30-12.30
Session Biology of Pathogen
​
Chair: Miguel Moreno, Violeta Valcheva
OR35 Melanie Grobbelaar Stellenbosch University
Evolution of drug resistance and treatment outcome within a longitudinal retrospective study – linking outcome to treatment.
​
OR33 Igor Mokrousov, St. Petersburg Pasteur Institute
Paleopathological and molecular evidence of tuberculosis in human skeletal remains from 18th-19th century Orthodox cemeteries in Irkutsk, Eastern Siberia
​
OR37 Joaquin Sanz, Universidad de Zaragoza - Instituto BIFI
Improving vaccine descriptions in model-based impact prognosis of new tuberculosis vaccines: removing arbitrariness and reducing bias.
​
OR38 Siavash Valafar, Chicago Medical School
Diversifying Evolution in Mycobacterium tuberculosis and Evasion of Molecular Diagnostics for Isoniazid (INH) Resistance is most prevalent in Asia
12:30-13.00
Poster Awards and Closing Ceremony
​
Chair: Daniela Maria Cirillo, Troels Lillebaek, Silva Tafaj
​